ABIVAX

Unternehmensprofil

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Beschreibung auf Englisch verfügbar.

Unternehmensdaten

Branche

Gesundheit

Industrie

Biotechnology

Land

Frankreich

Hauptsitz

7-11 Boulevard Haussmann, 75009, Paris

Mitarbeitende

98

Notierung

ABVX · Euronext Paris

Währung

EUR

ISIN

FR0012333284

Website

abivax.com